This material is educational and describes liraglutide and related molecules as research-use reagents. It is not medical advice, not a self-administration guide, and not a substitute for consulting a doctor.
Last updated: July 22, 2026.
Saxenda (liraglutide): this name comes up more often in conversations about weight control than in a pharmacy leaflet. Behind the brand is a specific substance: liraglutide, a GLP-1 receptor agonist. Longeva does not sell this branded drug. We work with liraglutide and related GLP-1-class molecules as research reagents and publish lab certificates of analysis (COA) for the batches we supply. This article covers what Saxenda and liraglutide are, how the GLP-1 class works, how liraglutide differs from semaglutide and tirzepatide, and where to look if you're interested in price, analogues, or reviews.
What Saxenda and liraglutide are
Saxenda is a trade name (trademark) of a drug. Liraglutide is the international nonproprietary name (INN) of the active substance it contains. The difference matters: the brand belongs to a specific manufacturer and a specific dosage form, while the molecule itself (liraglutide) can appear under different trade names and indications.
Brand vs. molecule: what's the difference
A trademark is a manufacturer's legal property over a specific name and dosage form. An international nonproprietary name is the name of the chemical substance itself, the same worldwide regardless of brand. That's why the same molecule is often sold under several trade names: liraglutide is registered both as Saxenda (for weight management) and as Victoza (for type 2 diabetes), both made by Novo Nordisk, but with different indications and maximum doses.
Manufacturer and regulatory status
The manufacturer of the branded Saxenda is the Danish company Novo Nordisk. In Ukraine, Saxenda is registered with the Ministry of Health (registration certificate UA/18651/01/01) and is dispensed strictly by prescription. That means the branded drug can legally be obtained only from a pharmacy on prescription, so any offer to buy it "without a prescription" outside the pharmacy network should raise questions about where it came from.
How liraglutide works: the GLP-1 class in plain terms
Liraglutide belongs to the GLP-1 (glucagon-like peptide-1) receptor agonist class, GLP-1 being a hormone the gut releases in response to food. The liraglutide molecule is 97% homologous to natural human GLP-1, with one key difference: it carries an attached fatty-acid chain that binds blood albumin and slows the molecule's breakdown. That modification is what allows liraglutide to be dosed once daily instead of multiple times, as would be needed with the natural hormone, which survives in blood for only minutes.
Activating the GLP-1 receptor has several parallel effects studied for this class:
- Central effect. GLP-1 receptors are present in the arcuate nucleus of the hypothalamus; their activation suppresses hunger signals.
- Slowed gastric emptying. Food stays in the stomach longer, so fullness sets in sooner and lasts longer.
- Glucose-dependent action on the pancreas. Stimulated insulin release and suppressed glucagon happen mainly when glucose is high, which is why the mechanism is described as "glucose-dependent".
The satiety signal also travels via the vagus nerve to the brainstem, and from there to the same hypothalamic neurons. This is the same "gut-brain axis" studied for the entire GLP-1-agonist class, not a property unique to one brand. It's important to be clear about the limits of this description: this is the class's mechanism of action per the scientific literature, not a promise of results for any individual, and not a self-administration guide.
That's exactly why this class of substances is so actively studied in labs: a single receptor target explains several physiological effects at once, rather than following a "one receptor, one outcome" pattern. Researchers are primarily interested in how changing the molecule's structure (fatty-acid chain length, receptor affinity, resistance to enzymatic breakdown) affects duration and profile of action, not in a ready-made conclusion about benefit for any particular person. That's the difference between a scientific description of a mechanism and a marketing promise of a result.
Liraglutide within the GLP-1 class: generations and comparison
Liraglutide, semaglutide, and tirzepatide belong to the same pharmacological family, incretin analogues, but they are not interchangeable synonyms. Each molecule is a separate stage in the class's development, with its own pharmacokinetics, and, in tirzepatide's case, a different set of receptor targets.
The word "generation" here isn't a marketing label, it's a way to describe a sequence of engineering decisions: each successive molecule in the class tried to solve a specific practical limitation of the one before it, most often dosing frequency and duration of action. That doesn't mean an older molecule is automatically worse or less safe: choosing a specific drug for treatment is always a doctor's decision based on the patient's condition, comorbidities, and indications, not the molecule's market-launch date.
Molecule comparison table
| Molecule | Brands (editorial) | Receptor(s) | Dosing frequency | Half-life |
|---|---|---|---|---|
| Liraglutide | Saxenda, Victoza | GLP-1 | daily | ≈13 h |
| Semaglutide | Ozempic, Wegovy (injection), Rybelsus (tablets) | GLP-1 | weekly (injection) / daily (tablets) | substantially longer than liraglutide |
| Tirzepatide | Mounjaro, Zepbound | GLP-1 + GIP (dual agonist) | weekly | ≈5 days |
Dosing frequency is directly tied to a molecule's half-life: the longer it stays in the blood, the less often an injection is needed. Liraglutide, with a half-life of roughly 13 hours, requires daily dosing; semaglutide's extended action allows weekly injection dosing; tirzepatide, with a half-life of about 5 days, is also dosed weekly.
Tirzepatide differs in duration of action and, more importantly, in mechanism: alongside the GLP-1 receptor, it also activates the GIP (glucose-dependent insulinotropic polypeptide) receptor, which is why it's described as a dual agonist rather than simply the next generation of the same molecule.
Brand vs. molecule: who's who
Confusion between trademark names and substances is often behind the "Saxenda vs Ozempic" search. Below is how brands and molecules currently map to each other; this is purely editorial information to explain the class, not a list of Longeva products:
- Saxenda and Victoza: both contain liraglutide, manufactured by Novo Nordisk.
- Ozempic, Wegovy, and Rybelsus: all three contain semaglutide, manufactured by Novo Nordisk.
- Mounjaro and Zepbound: both contain tirzepatide, manufactured by Eli Lilly.
Longeva does not sell any of the branded drugs listed above. Research versions of semaglutide, tirzepatide, and retatrutide are available in the incretin agonists catalog as reagents for laboratory research.
Liraglutide vs. semaglutide: what's the difference
The main practical difference is dosing frequency: liraglutide is injected daily, while semaglutide's injectable form only needs to be dosed once a week. That's not a manufacturer's whim but pharmacokinetics: structural changes in the semaglutide molecule give it stronger albumin binding and resistance to enzymatic breakdown, so the substance stays active in the blood longer.
This difference also affects practical use: a less frequent injection schedule means fewer reminders and an easier fit into a weekly routine. In head-to-head studies, semaglutide on average showed a stronger effect on body weight than liraglutide. But the conclusion "which is better for weight loss" is not valid outside the context of a specific dose, study, and clinical goal, that decision always belongs to a doctor, not brand marketing.
The GLP-1 drug market is moving toward molecules with less frequent dosing not because the daily form is inherently outdated, but because fewer injections reduce patient burden and improve adherence to long-term therapy. For a more detailed look at semaglutide, its supply forms, and COAs, see the semaglutide (research-grade) page.
Saxenda: price in Ukraine and where to buy
Saxenda is a prescription drug, dispensed in Ukraine strictly by a doctor's prescription. It can legally be obtained only at a pharmacy, and the price depends on dosage, the number of pens per pack, the specific pharmacy chain, and the exchange rate. We deliberately don't quote a hryvnia figure here: any number would go stale faster than this article, and the current cost is best confirmed directly at a pharmacy. Longeva also does not sell or set a price for this branded drug, so a "saxenda price" query is best addressed to a pharmacy chain, not a supplier of research reagents.
Why Saxenda is prescription-only
Registering a drug for long-term weight control comes with medical supervision for a reason: the dose is titrated gradually, and the drug has contraindications and requires caution in a number of conditions that a doctor assesses during an exam. The prescription status here is functional, it guarantees medical supervision at every dose-escalation step, not bureaucracy for its own sake. So any offer to buy such a drug "without a prescription" outside the pharmacy network should raise doubts about where it came from.
Research-grade GLP-1 materials in stock
What Longeva actually does is supply liraglutide and related GLP-1/GIP-class molecules as research-use reagents, not as substitutes for a pharmaceutical brand and not as a treatment. The lineup includes semaglutide, tirzepatide, and retatrutide, each batch accompanied by a certificate of analysis (COA) from an independent third-party lab. The full lineup in this category is in the incretin agonists catalog.
Saxenda reviews: how to read them
A "saxenda reviews" search usually leads to pages of impressions from people who've used the drug. The key thing to understand: a single review isn't evidence of efficacy or safety, it's a description of one person's experience, shaped by their weight, comorbidities, and dose. Reactions to GLP-1 drugs vary by individual: in liraglutide's registration trials, some participants reported nausea during dose escalation, while others tolerated treatment without noticeable discomfort. None of these stories, taken alone, proves anything for anyone else.
When reading reviews, it's worth checking a few things: does the author describe a specific dose and duration of use, are they talking about an official pharmacy product or an item from an unknown source, and does an emotional verdict ("amazing", "doesn't work") stand in for any actual verified data. Pages full of suspiciously uniform "perfect" reviews, with no dates, no dosing details, and no link to any document, are a classic sign of manufactured content, not real experience.
What a review can never prove is the purity and composition of a specific vial or pen. Only a lab analysis of the batch can prove that, not the subjective impression of someone who never even saw a certificate for their own product. That's exactly why Longeva points researchers to the COA archive: it documents a specific batch, whereas someone else's review remains just one person's subjective impression.
How to verify purity: COAs from independent labs
A COA (Certificate of Analysis) is a lab document confirming a substance's identity and purity based on analysis of a specific batch. It's not an advertising promise, it's a verifiable lab result that can be matched against the batch physically sitting on a researcher's bench.
Longeva independently sends samples for analysis to independent third-party labs rather than relying on documents from a raw-material supplier. Labs Longeva works with include Janoshik, Testides, Uzorak, and North American Diagnostics. Important clarification: none of them holds ISO 17025 accreditation, and in general, none of the commonly used independent labs for research-use peptides in this market hold that accreditation. So the accurate wording is "independent third-party lab," not "accredited lab." Any source claiming otherwise is mistaken or misleading.
Batches ship with a COA, and results are published in the open COA archive, where each lot can be verified individually at /verify/{lot}. That's exactly the kind of proof no review can offer: independently confirmed identity and purity for a specific batch.
Research status and what to keep in mind
Liraglutide and related GLP-1-class molecules that Longeva supplies are research-use reagents for laboratory research, not medicines and not dietary supplements. That's a description of the product's legal and practical status, and it doesn't diminish its quality in any way: the decision to use any substance in this class to treat a person is made by a doctor based on a registered drug, not by a research-reagent supplier.
In the SCALE registration trial, nausea was recorded in 39.3% of participants receiving liraglutide 3.0 mg, versus 13.8% on placebo, most often during dose escalation. That's a figure for the registered drug from the manufacturer's own data, a general characteristic of the class from the brand's registration trials, not a guarantee for a research reagent, and not a reason to ignore individual contraindications, which a doctor determines.
Dosing: where to look
This article deliberately does not include a dosing schedule or injection instructions: dosing is research context, not a how-to guide, so it lives on a separate reference page. For semaglutide, the most closely studied analogue in this class, that schedule with source references is collected on the semaglutide dosing page.
Frequently asked questions
Is liraglutide the same as Saxenda?
No, these are different levels of the same concept. Liraglutide is the molecule (the active substance), while Saxenda is the trade name of one drug based on that molecule, registered for weight management. The same substance, under a different name and dose, is registered as Victoza for type 2 diabetes.
Is Saxenda the same as Ozempic?
No. Saxenda is a brand of liraglutide, while Ozempic is a brand of a different molecule, semaglutide, the next generation of the same GLP-1-agonist class. The practical difference: liraglutide is injected daily, while semaglutide is injected weekly. Both are prescription drugs, and Longeva neither sells nor supplies either of them as a medicine.
Does Longeva sell Saxenda?
No. Longeva does not sell or supply any branded drug, including Saxenda, Victoza, Ozempic, or Mounjaro. We supply researchers with liraglutide and related GLP-1/GIP-class molecules, such as semaglutide, tirzepatide, and retatrutide, as research-use reagents with COAs from independent labs, not as substitutes for pharmaceutical brands.
How much does Saxenda cost?
We don't quote a price for Saxenda: it's a branded prescription drug that Longeva doesn't sell, and pharmacy pricing depends on dosage, chain, and exchange rate, so the current figure is best confirmed there directly. If you're interested in research-use liraglutide or related GLP-1 molecules with COAs, see the incretin agonists catalog.
What can replace Saxenda?
There's no direct brand "replacement", the treatment decision always belongs to a doctor. In a research context, liraglutide and related GLP-1/GIP-class molecules, semaglutide, tirzepatide, retatrutide, are available as research-use reagents with independent lab-confirmed purity (COA), not as a pharmacy substitute for the prescription drug.
Where to go next: Longeva's GLP-1 materials and references
If your goal is research work with GLP-1/GIP-class molecules rather than finding a branded drug, here are direct links on the topic:
- Semaglutide (research-grade): the class's next generation, weekly dosing, COA in the archive.
- Tirzepatide: dual GLP-1/GIP agonist.
- Retatrutide: a triple agonist in the same research direction.
- Incretin agonists catalog: the full lineup of GLP-1/GIP molecules with COAs.
- COA archive: verify batches from independent labs.
- Semaglutide dosing: a reference schedule for research context.
Each of these pieces covers a different part of the picture: from a specific molecule to confirmation of its purity. Together they form a research path for anyone who arrived via a Saxenda search and wants to go further, into the GLP-1 class as a whole.
